(Q41964351)

14 October 2017

title

Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy (English)

1 reference

14 October 2017

1 reference

Naohiro Sekiguchi

1

1 reference

14 October 2017

Kaori Ootsubo

2

1 reference

14 October 2017

Miyuki Wagatsuma

3

1 reference

14 October 2017

Kiyoe Midorikawa

4

1 reference

14 October 2017

Akihisa Nagata

5

1 reference

14 October 2017

Satoshi Noto

6

1 reference

14 October 2017

Kazuaki Yamada

7

1 reference

14 October 2017

Naoki Takezako

8

1 reference

14 October 2017

language of work or name

1 reference

5 February 2014

1 reference

International Journal of Hematology

14 October 2017

published in

1 reference

14 October 2017

volume

99

1 reference

14 October 2017

issue

3

1 reference

14 October 2017

page(s)

288-295

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-014-1514-1

14 October 2017

exact match

0 references

cites work

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Genetic events in the pathogenesis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Molecular pathogenesis of multiple myeloma and its premalignant precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Clonal competition with alternating dominance in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Molecular pathogenesis of multiple myeloma: basic and clinical updates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Update on risk stratification and treatment of newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Double-hit B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1514-1

Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.

21 January 2018

1 reference

12 December 2020

Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hé

1 reference

12 December 2020

High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents

1 reference

12 December 2020

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

12 December 2020

Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes.

1 reference

12 December 2020

Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma

1 reference

12 December 2020

10.1007/S12185-014-1514-1

Identifiers

DOI

1 reference

14 October 2017

1 reference